Solomon Moshkevich Sells 3,000 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $320.73, for a total transaction of $962,190.00. Following the transaction, the insider owned 126,019 shares of the company’s stock, valued at approximately $40,418,073.87. The trade was a 2.33% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, September 2nd, Solomon Moshkevich sold 15,160 shares of Natera stock. The stock was sold at an average price of $326.89, for a total transaction of $4,955,652.40.
• On Monday, August 3rd, Solomon Moshkevich sold 3,410 shares of Natera stock. The stock was sold at an average price of $265.58, for a total transaction of $905,627.80.
• On Tuesday, July 28th, Solomon Moshkevich sold 1,204 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $305,900.28.
• On Monday, July 27th, Solomon Moshkevich sold 1,010 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $263,094.90.
• On Wednesday, July 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The shares were sold at an average price of $272.90, for a total value of $818,700.00.

Natera Trading Up 0.2%

NASDAQ NTRA opened at $328.18 on Friday. The stock has a market capitalization of $47.30 billion, a price-to-earnings ratio of -241.31 and a beta of 1.54. The business’s 50 day moving average is $292.62 and its two-hundred day moving average is $237.63. Natera, Inc. has a 12-month low of $157.43 and a 12-month high of $343.18.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period last year, the firm earned ($0.74) EPS. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. Equities analysts forecast that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on NTRA. Sanford C. Bernstein assumed coverage on shares of Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 price target on the stock. Stephens raised their price objective on shares of Natera from $305.00 to $350.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. UBS Group set a $260.00 price objective on shares of Natera in a report on Wednesday, June 24th. Leerink Partners set a $330.00 target price on shares of Natera in a research report on Friday, August 7th. Finally, Barclays reaffirmed an “overweight” rating and issued a $340.00 target price on shares of Natera in a report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $319.38.

Hedge Funds Weigh In On Natera

Several hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new position in Natera in the 2nd quarter valued at about $2,962,770,000. K.J. Harrison & Partners Inc purchased a new stake in shares of Natera during the second quarter worth about $5,117,000. Abbot Financial Management Inc. acquired a new position in shares of Natera in the second quarter valued at approximately $1,537,000. Eagle Health Investments LP acquired a new position in shares of Natera in the second quarter valued at approximately $4,302,000. Finally, Fifth Third Bancorp lifted its stake in shares of Natera by 3,373.1% during the first quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock valued at $2,251,000 after buying an additional 10,929 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.